Immune Correction Using Interleukin-1β at Moderate and Severe HSV-Infection
A. M. Kurmanova
Scientific Centre of Obstetric, Gynecology and Perinatology of Ministry of Healthcare and Social Development, Almaty, Republic of Kazakhstan
G. М. Kurmanova
Kazakh National Medicinal University, Almaty, Republic of Kazakhstan.
L. K. Smailova *
Scientific Centre of Obstetric, Gynecology and Perinatology of Ministry of Healthcare and Social Development, Almaty, Republic of Kazakhstan. and JSC, Astana Medical University, Astana, Republic of Kazakhstan.
*Author to whom correspondence should be addressed.
Abstract
Inclusion of interleukin-1β into complex therapy of severe forms of herpes recurrent, allows to remove very effectively immune disturbances and to prevent occurrence of new infection relapses. Prophylactic prescription of interleukin-1β during remission period of herpes recurrent also demonstrated advisability of the therapy. On the background of therapy with interleukin-1β, 12 patients had remission duration. So, in 10 patients prior to therapy with interleukin-1β, remission duration was 1.5 – 2 months, and after the therapy in 9 of them it increased to 10 – 11 months. In 5 female patients, remission duration was 2 – 3 months, after the treatment using interleukin-1β remission lasted more than 12 months. 3 patients during 2-year follow-up had no relapses at all. Anti-recurrent effect of interleukin-1β is related with immunomodulatory properties of the preparation, consisting of increased content of ripe lymphocytes and active lymphocytes (CD25+), as well as increased values of spontaneous and induced LPS NBT-test.
Keywords: HSV-infection, immunity, cytokines, phagocytosis, Interleukin-1β (Betaleukin)